Leber’s hereditary optic neuropathy,LHON
Conditions
Interventions
Control group:to give placebo 150mg/time,3 times/day
control group:Mecobalamin Tablets 0.5mg / time, three times / day
Control group:Vitamin B1 tablets 10mg/ time, three times / day
observation group:to give Idebenone 150mg/time,3 times/day
observation group:Mecobalamin Tablets 0.5mg / time, three times / day
observation group:Vitamin B1 tablets 10mg/ time, three times / day
Sponsors
Beijing Tongren Hospital, CMU
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of LHON in clinical ophthalmology, edited by Kanski; 2. At least one common major mutation :m.G11778Am.T14484Cm.G3460Am.G3635A[10-16] 3. 18 years of age or older; 4. Painless central vision decline and successively common binocular disease,But the interval is less than 1 years duration less than 5 years; 5. the patient or the patients legal representative have provided singed written informed consent.
Exclusion criteria
Exclusion criteria: 1. other diseases that cause optic nerve injury: intracranial tumors, optic neuritis, multiple sclerosis, ischemic, radioactive, toxic and other optic nerve diseases. 2. patients with other ocular diseases that cause visual dysfunction, such as uveitis and irises, etc. 3. serious abnormal liver function (alt, AST AST ALT > 3 times the upper limit of normal reference value); 4. women in pregnancy and lactation; 5. poor compliance and poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of visual acuity before and after treatment (including anterior index and anterior hand);The distribution of visual acuity before and after treatment of different loci (recommended by the Wenzhou star Kang standard logarithmic visual acuity chart); | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of visual field before and after treatment (suggested using Humphrey field of vision);Changes in visual evoked potential (P-VEP) (recommended using German Roland RETI);OCT detection of retinal thickness changes (recommended useing Heidelberg OCT, Germany or Zeiss OCT, Germany); | — |
Countries
China
Contacts
Public ContactWang Jiawei
Beijing Tongren Hospital,CMU
Outcome results
None listed